Clinical Trial ProgressInventiva has completed enrollment of the NATiV3 trial, marking a major milestone for the company as it prepares for topline data in the second half of 2026.
Competitive AdvantageLanifibranor could have a significant competitive advantage in the MASH + T2D patient subpopulation if effects observed in previous trials are confirmed in NATiV3.
Financial SupportCompletion of NATiV3 enrollment would unlock two key financing components, providing about €125M in funding to extend its cash runway.